GI
SNDX icon

GAMMA Investing’s Syndax Pharmaceuticals SNDX Stock Holding History

GAMMA Investing’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9.12K Buy
417
+25
+6% +$520 ﹤0.01% 3257
2026
Q1 		$9.16K Buy
392
+112
+40% +$2.43K ﹤0.01% 3111
2025
Q4 		$5.88K Buy
280
+95
+51% +$1.66K ﹤0.01% 3214
2025
Q3 		$2.85K Buy
185
+142
+330% +$1.86K ﹤0.01% 3358
2025
Q2 		$403 Sell
43
-36
-46% -$396 ﹤0.01% 3658
2025
Q1 		$971 Sell
79
-18
-19% -$254 ﹤0.01% 3565
2024
Q4 		$1.28K Buy
97
+8
+9% +$137 ﹤0.01% 3351
2024
Q3 		$1.71K Sell
89
-1
-1% -$21 ﹤0.01% 3116
2024
Q2 		$1.85K Buy
90
+21
+30% +$439 ﹤0.01% 2901
2024
Q1 		$1.64K Buy
69
+49
+245% +$1.09K ﹤0.01% 2805
2023
Q4 		$410 Buy
+20
New +$307 ﹤0.01% 3003

Other funds holding SNDX

HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return
YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return
TE
Tema ETFs New York $3.09B AUM 72.72% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
DT
Diversified Trust Memphis, Tennessee $6.24B AUM 28.78% 1-Year Est. Return
HCA
Harbour Capital Advisors Tysons Corner, Virginia $549M AUM 54.99% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return
PR
PSP Research Newtown Square, Pennsylvania $188M AUM
PRTG
Post Resch Tallon Group Pittsford, New York $145M AUM 25.19% 1-Year Est. Return
VCM
Versant Capital Management Phoenix, Arizona $1.12B AUM 34.21% 1-Year Est. Return

GAMMA Investing's SNDX Position: Q2 2026 in Review

GAMMA Investing increased its Syndax Pharmaceuticals (SNDX) stake by 6.4% in Q2 2026, buying an estimated $520 and bringing the position to 417 shares worth $9.12K. The position accounts for ﹤0.01% of the portfolio, ranked #3257.

GAMMA Investing first reported a position in SNDX in Q4 2023 and has held it in 11 quarters since. The position peaked at $9.16K in Q1 2026. 17 funds tracked by Wall St. Rank hold SNDX as of Q2 2026.

  • GAMMA Investing held 417 shares of Syndax Pharmaceuticals worth $9.12K as of Q2 2026.
  • GAMMA Investing bought 25 Syndax Pharmaceuticals shares in Q2 2026, an estimated $520.
  • Syndax Pharmaceuticals made up ﹤0.01% of GAMMA Investing's portfolio in Q2 2026, its #3257 holding.
  • GAMMA Investing first reported a position in Syndax Pharmaceuticals in Q4 2023 and has held it in 11 quarters since.
  • GAMMA Investing's Syndax Pharmaceuticals position peaked at $9.16K in Q1 2026.
  • 17 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q2 2026.

Based on GAMMA Investing's 13F filing for Q2 2026, filed 7 Jul 2026.